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Abstract
Background: The process of elimination of intracellular pathogens, such as Leishmania, requires a Th1
type immune response, whereas a dominant Th2 response leads to exacerbated disease. Experimental
human zinc deficiency decreases Th1 but not Th2 immune response. We investigated if zinc and copper
levels differ in different clinical forms of leishmaniasis, and if these trace metals might be involved in the
immune response towards the parasite.
Methods: Blood was collected from 31 patients with either localized cutaneous (LCL), mucosal (ML) or
visceral (VL) leishmaniasis, as well as from 25 controls from endemic and non-endemic areas. Anti-
Leishmania humoral and cellular immune response were evaluated by quantifying specific plasma IgG,
lymphoproliferation and cytokine production, respectively. Plasma levels of Cu and Zn were quantified by
atomic absorption spectrophotometry.
Results: A significant decrease in plasma Zn was observed in all three patient groups (p < 0.01 for LCL
and ML, p < 0.001 for VL), as compared to controls, but only VL (7/10) and ML (1/7) patients displayed
overt Zn deficiency. Plasma Cu was increased in LCL and VL (p < 0.001) but not in ML, and was strongly
correlated to anti-Leishmania IgG (Spearman r = 0.65, p = 0.0028). Cu/Zn ratios were highest in patients
with deficient cellular (VL<<LCL<ML) and exacerbated humoral (VL>LCL>ML) immune response. Ex vivo
production of parasite-induced IFN-γ was negatively correlated to plasma Cu levels in LCL (r = -0.57, p =
0.01). In vitro, increased Cu levels inhibited IFN-γ production.
Conclusions: 1. Zn deficiency in VL and ML indicate possible therapeutic administration of Zn in these
severe forms of leishmaniasis. 2. Plasma Cu positively correlates to humoral immune response across
patient groups. 3. Environmentally or genetically determined increases in Cu levels might augment
susceptibility to infection with intracellular pathogens, by causing a decrease in IFN-γ production.
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Background
Leishmaniasis is endemic in several parts of the world,
with a global prevalence of over 12 million cases and 1.5–
2 million new cases emerging every year [1]. The infection
is caused by protozoan parasites of the genus Leishmania,
transmitted through the bite of the sand fly vector. Several
Leishmania species are able to cause a wide spectrum of
clinical manifestations, ranging from the mild cutaneous
form, the disfiguring mucosal form and the life-threaten-
ing visceral form, also known as kala-azar. In Brazil, Leish-
mania (L.) braziliensis causes cutaneous and mucosal
disease,  L. amazonensis causes cutaneous and, sporadi-
cally, visceral disease, while L. chagasi is exclusively asso-
ciated with visceral disease. The clinical outcome of
infection thus not only depends on the species involved,
but also on the patient's immunocompetence. In recent
years, a protective immune response against intracellular
pathogens, such as Leishmania, Listeria and mycobacteria,
has been defined as type 1 (Th1), whereas protection
against extracellular pathogens, such as helminths,
requires a type 2 (Th2) response. The murine model of
experimental leishmaniasis has been instrumental for the
elaboration of the Th1/Th2 paradigm, inasmuch as the
preferential action of Th1 (IFN-γ, IL-12, TNF-α) or Th2
cytokines (IL-4, IL-5, IL-10) results in cure or progression
of the disease, respectively [2,3]. In human leishmaniasis,
this Th1/Th2 dichotomy is much less explicit for in vitro
or ex vivo cytokine production. However, striking differ-
ences in cellular (lymphoproliferation and IFN-γ produc-
tion) and humoral (total and anti-Leishmania  IgG)
immune response can be observed in different clinical
forms of the disease. Our group has recently shown that
patients with localized cutaneous leishmaniasis (LCL)
display a diminished Th1 response during the early phase
of disease, which is reverted after treatment [4]. In
mucosal leishmaniasis (ML), on the other hand, an exac-
erbated Th1 response with increased IFN-γ and TNF-α lev-
els, is believed to provoke tissue destruction [5]. In
patients with visceral leishmaniasis (VL), characterized by
immunosuppression and absence of IFN-γ production
[6], we were able to show the beneficial effect IFN-γ in vivo
[7]. Although zinc deficiency has been shown to lead to a
selective Th1 deficiency in human volunteers [8], only few
data are available on the role of trace elements in human
leishmaniasis, being restricted to Old World LCL, show-
ing increased serum copper and decreased serum zinc in
Turkish LCL patients infected by L. major [9]. In this study,
we investigated if Zn and Cu levels differ in different clin-
ical forms of the disease, and if these trace metals might
be correlated to anti-parasite immune response.
Methods
Blood samples (10 ml heparinized tubes, Vacutainer)
from 21 patients and 15 healthy controls (mostly patient's
relatives) were obtained in an outpatient clinic in the dis-
trict of Corte de Pedra, (Bahia state, Northeast of Brazil).
This rural area has a low socio-economic status and a high
incidence of infection with Leishmania braziliensis and,
sporadically, Leishmania amazonensis. During a one year
period, 14 patients with LCL (single lesion with less than
4 weeks of duration) were selected and treated (20 mg/kg
of Sb (Glucantime) i.v. during 20 days). Of those, only 7
patients returned to draw blood after 3 months of treat-
ment, but all patients cured during follow-up. Seven
patients with ML were selected after several rounds of
unsuccessful treatment and severe disease progression.
Blood samples from 10 patients (at diagnosis, before
treatment) with VL were obtained from two different
urban areas (Salvador-Bahia and Teresina-Piaui). Ten
healthy urban controls were recruited among students
and laboratory staff (Salvador-Bahia). Diagnosis was con-
firmed by Montenegro skin test, serology, direct culture of
parasites from lesions [4] or bone marrow aspiration for
VL [7]. This study was approved by the Ethics Committee
of the University Hospital Edgard Santos, Salvador.
Cu and Zn were quantified by atomic absorption spectro-
photometry (Varian 220) using an air/acetylene flame.
One ml of plasma was diluted tenfold with 0.05 % Triton
X-100, 1 % HNO3, sonicated for 10 min and analyzed in
triplicate. All reagents used were analytical grade (Merck).
Due precautions were taken to avoid external and internal
(hemolysis) trace metal contamination.
In order to investigate the influence of trace metals, anti-
bodies and other endogenous plasma components, such
as cytokines, on the ex vivo cellular immune response, we
used a recently described model using whole blood and
live Leishmania promastigotes [10], closely mimicking the
early in vivo events following a sandfly bite. Whole blood
was diluted tenfold in culture medium (RPMI supple-
mented with L-glutamine and gentamycin, all from
Gibco-BRL) and stimulated with L. amazonensis promas-
tigotes (105/mL). Buffy coats from normal blood donors
were used to obtain large quantities of cells required for in
vitro experiments to examine the effect of exogenous trace
metals upon cytokine production. Mononuclear cells
were separated by density gradient centrifugation (Ficoll-
Paque, Pharmacia, Uppsala, Sweden) and cultured in
complete culture medium (supplemented with 10 % fetal
calf serum, Gibco-BRL). Cu and Zn concentrations were
below the detection limit in RPMI and less than 2 µM in
complete culture medium. Supernatants were collected
after 72 h of culture and frozen in aliquots for cytokine
determination. Lymphoproliferation was quantified by
measuring [H]-thymidine incorporation after 120 h of
culture. IFN-γ, TGF-β1, TNF-α and IL-5 in plasma or cul-
ture supernatants were quantified using commercial
ELISA kits (DuoSet, R&Dsystems). All results are
expressed as mean ± SEM. Statistical evaluation of dataBMC Infectious Diseases 2004, 4:50 http://www.biomedcentral.com/1471-2334/4/50
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was performed using GraphPad Prism software: Mann-
Whitney test for comparing patients and control groups,
Spearman rank test for correlation and Wilcoxon signed
rank test for comparing in vitro treatments; a p-value <0.05
was considered significant.
Results
A significant decrease in plasma Zn was observed for both
LCL and ML patients, as compared to controls from the
same endemic area (0.80 ± 0.04 and 0.77 ± 0.05 vs. 1.01
± 0.06 µg/mL, p < 0.01, Figure 1A), and in VL patients, as
compared to urban controls (0.55 ± 0.08 vs. 0.83+/-0.03
µg/mL, p < 0.001, Figure 1A). Zn deficiency (plasma Zn
<0.65 µg/mL), however, was observed only in VL (7/10)
and ML (1/7) patients. As shown in Fig. 1B, plasma Cu
was significantly increased in LCL (1.32 ± 0.10 vs. 1.01 ±
0.05 µg/mL, p < 0.001) and VL (1.42 ± 0.13 vs. 0.72 ± 0.06
µg/mL, p < 0.001), but not in ML (1.04 ± 0.05 vs. 1.01 ±
0.05 µg/ml). After three months of treatment, plasma Zn
increased and Cu decreased in LCL patients, resulting in
values indistinguishable from endemic controls.
Although within normal physiological ranges [11], Cu
and Zn levels were significantly increased in healthy con-
trols from the endemic area, as compared to urban con-
trols (p < 0.01, Fig, 1A and 1B). Cu/Zn ratios, however,
were similar in both control groups (p = 0.12), but signif-
icantly increased in all three patient groups (Fig. 1C),
reaching a three-fold molar excess of Cu to Zn in VL
patients.
To determine if these observations reflect possible
changes in the patients' immune status, we quantified
humoral and cellular anti-Leishmania immune response ex
vivo and correlated them to trace element levels. When
comparing patient groups, a stepwise increase in anti-
Leishmania IgG and Cu/Zn ratio can be observed, with
ML<LCL<VL (Table 1 and Fig. 1). In addition, a highly sig-
nificant correlation between plasma Cu, but not Zn or Cu/
Zn ratio, and anti-Leishmania  IgG was observed across
patient groups (Fig. 2, Spearman r = 0.65, p = 0.0028).
Since lymphoproliferation and IFN-γ production were vir-
tually absent in VL, correlation with trace element levels
across patient groups could not be calculated, but an
inverse order was observed, with ML>LCL>>VL (Table 1)
as compared to Cu/Zn ratio with ML<LCL<<VL (Fig. 1),
confirming reciprocal regulation of Th1/cellular immune
response and Th2/humoral immune response. However,
we found a significant negative correlation between
plasma Cu and ex vivo IFN-γ production (Spearman r = -
0.86, p = 0.024) in untreated patients only, whereas no
significant correlation was observed for Leishmania-or
mitogen-induced lymphoproliferation, TGF-β1, TNF-α
and IL-5 levels in plasma or culture supernatants (not
shown). To verify the hypothesis that increased Cu levels
might down-regulate IFN-γ production, we added Cu (10
µM, corresponding to the increase of plasma Cu observed
ex vivo in LCL patients) to mitogen-or anti-CD3-stimu-
lated in vitro cultures from healthy controls. As shown in
Figure 3, 10 µM of CuCl2 significantly decreased anti-
CD3-induced IFN-γ production (40.5 ± 9.3 % inhibition,
p < 0.05). Interestingly, the addition of physiological con-
centrations of Zn (10–30 µM) to ex vivo or in vitro cultures
did not revert the apparently inhibitory effect of endog-
enous or exogenous Cu on IFN-γ secretion. (not shown).
Discussion
Although plasma Zn was significantly decreased in all
three patient groups, plain Zn deficiency was only
observed in seven VL patients and one ML patient, being
absent in LCL patient and in both control groups. In par-
allel, plasma Cu in VL patients increased to levels which
have been shown to be toxic in vitro [12]. In addition, a
highly significant positive correlation between plasma Cu
and parasite-specific IgG across patient groups suggests
that the trace element might interfere in anti-Leishmania
immune response, e.g. by leading to a non-protective
Th2/humoral immune response, known to be exacerbated
in visceral leishmaniasis. Increased plasma Cu cannot be
considered as a mere marker of inflammation, since it was
not observed in ML, a chronic inflammatory condition
characterized by high production of pro-inflammatory
cytokines, such as TNF-α and IFN-γ [5]. Absence of corre-
lation between TNF-α and trace metal levels underscores
the specificity of the inhibitory effect of Cu upon IFN-γ
production, which might in fact be the upstream event to
an increased humoral anti-Leishmania response.
Since our in vitro findings indicate Zn as a monocyte/mac-
rophage activator [13], the significant decrease in Zn in
ML patients might be responsible for the inability of the
patients to clear the parasite, in spite of high IFN-γ levels
and several rounds of treatment. LCL patients represent an
intermediate group between ML and VL, displaying a
detectable, but variable humoral and cellular immune
response with production of both Th1 and Th2 cytokines,
undergoing a shift towards the Th1/cellular pole after suc-
cessful treatment [4]. We observed a reciprocal association
between Cu/Zn levels and humoral and cellular immune
response between the three patient groups (Table 1 and
Fig. 1), as well as a complete reversal of increased Cu/Zn
ratios after treatment in LCL patients. Taken together,
these data indicate that Cu/Zn imbalance might serve as a
marker for decreased Th1 response and immunodefi-
ciency in leishmaniasis, being more pronounced in its
most severe and possibly fatal visceral form. Unfortu-
nately, no clinical follow-up was possible in VL patients,
but mortality, mostly due to co-infections, and therapeu-
tic failure occur in 6,1 % of the cases [14,15].BMC Infectious Diseases 2004, 4:50 http://www.biomedcentral.com/1471-2334/4/50
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Plasma levels of Zn and Cu in controls and patients Figure 1
Plasma levels of Zn and Cu in controls and patients. Bars represent mean (+/-SEM) Zn (A) and Cu (B) plasma levels, 
and plasma Cu/Zn ratios (C) of urban (U) and endemic (E) controls; and patients with mucosal leishmaniasis (ML), localized 
cutaneous leishmaniasis before (LCL0) and after 3 months of treatment (LCL3), and visceral leishmaniasis (VL). *p < 0.05, **p 
< 0.01, ***p < .001 for LCL0 and ML vs. E and for VL vs. U (Mann-Whitney test).BMC Infectious Diseases 2004, 4:50 http://www.biomedcentral.com/1471-2334/4/50
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It is tempting to speculate that environmental exposure to
copper might increase susceptibility to Leishmania  and
other intracellular pathogens, such as Listeria and myco-
bacteria, e.g. by directly interfering with cytokine produc-
tion as previously shown [16]. Increased plasma Cu in
endemic controls might reflect the use of Cu as a fungicide
in cocoa plantations in the Corte de Pedra area. It should
be stated that spouses and relatives were preferentially
chosen as endemic controls, since environmental expo-
sure and nutritional status are far more important deter-
minants for Cu and Zn levels than sex or age [11]. In
addition, (epi)genetic factors related to copper homeosta-
sis might render normal individuals more susceptible to
Table I: Characteristics and immune parameters of patient groups and controls
Group (n) Age Male/Female Anti-Leishmania IgG (O.D.) Lympho-proliferation (cpm)b IFN-γ (pg/ml)b
Urban controls (10) 24.9 (2.0) 7/3 < cut-off < 100 < 20
Endemic controls (15) 28.7 (8.8) 3/12 < cut-offa ND < 20
LCL0 (14) 28.4 (12.7) 10/4 0.178 (0.073) 2737 (1178) 612 (207)
LCL3 (7) 28.5 (11.2) 5/2 0.074 (0.021) ND 685 (348)
ML (7) 44.4 (11.9) 5/2 0.016 (0.005) > 5000 > 2000
VL (10) 18.4 (3.8) 6/4 0.188 (0.072) < 100 < 20
Results are expressed as mean (SEM). ND: not done. LCL0 and LCL3, localized cutaneous leishmaniasis at 0 and 3 months of treatment, ML 
mucosal leishmaniasis, VL visceral leishmaniasis.
a One endemic control displayed positive serology and was discarded from analysis.
b Following stimulation of tenfold diluted whole blood with live Leishmania promastigotes.
Correlation between plasma Cu and anti-Leishmania IgG Figure 2
Correlation between plasma Cu and anti-Leishmania 
IgG. Plasma levels of Cu and anti-Leishmania IgG were posi-
tively correlated in patients with localized cutaneous leishma-
niasis before treatment (LCL), mucosal leishmaniasis (ML) 
and visceral leishmaniasis (VL) (Spearman r = 0.65, p = 
0.0028).
In vitro effects of exogenous Cu upon IFN-γ production in  healthy controls Figure 3
In vitro effects of exogenous Cu upon IFN-γ produc-
tion in healthy controls. Mononuclear cells from normal 
donors were incubated for 48 h in the absence or presence 
of anti-CD3 (200 ng/ml), Cu (10 µM CuCl2) or both. Bars 
represent mean (+/-SEM) IFN-γ concentration in superna-
tants from six different donors. Unstimulated cells or cells 
stimulated with Cu alone did not produce IFN-γ. *p < 0.05 vs. 
anti-CD3-stimulated cells (Wilcoxon signed rank test).BMC Infectious Diseases 2004, 4:50 http://www.biomedcentral.com/1471-2334/4/50
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copper toxicity [17]. Thus, increased Cu levels and
decreased Zn levels might be a cause, rather than a conse-
quence of LCL. On the other hand, absence of Cu increase,
linked to uncontrolled IFN-γ production, might underlie
evolution towards ML. Long-term follow-up of treated
patients and comparison with other endemic areas might
learn if trace metal levels have predictive value for clinical
evolution of and/or susceptibility to leishmaniasis. In
addition, we propose that trace metal levels should be
taken into account in vaccine strategies for leishmaniasis,
because of the importance of Zn in a protective Th1
response [8] and because of the possibly deleterious effect
of Cu described in this study. Two recent large-scale vacci-
nation trials for cutaneous and visceral leishmaniasis
[18,19] were carried out in regions where Zn deficiency is
prevalent, namely Iran and Sudan, which might have con-
tributed in part to the low protection rate observed in
both trials.
Administration of Zn in vivo has been shown to down-
regulate increased Cu levels in patients with Wilson dis-
ease and to revert its toxicity [20], suggesting that systemic
administration of Zn might be beneficial in addition to its
direct immunostimulatory effect [8]. A recent report [21]
demonstrated the safety and efficiency of oral Zn in Old
World cutaneous leishmaniasis, a mild and self-healing
form of the disease, with patients displaying normal Zn
levels. Our results strongly suggest that zinc therapy
should be considered in the mucosal and visceral forms of
leishmaniasis, associated with high morbidity and mor-
tality, as well as frequent failure of antimonial therapy.
Conclusions
Zn deficiency in visceral and mucosal leishmaniasis indi-
cate possible therapeutic administration of Zn in these
severe forms of leishmaniasis. Plasma Cu positively corre-
lates to (non-protective) humoral immune response
across patient groups, and reciprocally, increased Cu lev-
els decreased in vitro (protective) IFN-γ production, imply-
ing that environmentally or genetically determined
increases in Cu levels might augment susceptibility to
infection with intracellular pathogens. Our data indicate
that Cu/Zn imbalance can be a useful marker for immune
dysfunction in leishmaniasis and suggest that trace metals
are implicated in both humoral and cellular anti-Leishma-
nia immune response, which should inspire future strate-
gies for therapy and immunoprophylaxis of human
leishmaniasis.
Competing interests
The author(s) declare that they have no competing
interests.
Authors' contributions
JVW designed the scientific project, analyzed the data and
wrote the paper. GS was responsible for sample process-
ing and data collection. AD selected LCL and ML patients,
as well as controls from the endemic area. CHC selected
VL patients. AFS did the trace metal analysis. AB and EMC
supervised the field work and reviewed the paper. MBN
analyzed the data and reviewed the paper.
Acknowledgements
We thank the patients, their families, the field workers and the medical staff 
from the Corte de Pedra outpatient clinic; André Bafica, Cristiano Bahia, 
Daniele Decanine, George Soares, Jorge Tolentino, Maria da Purificaçao 
Silva and Silvia Cardoso for practical assistance; Dr Maria das Graças 
Korner for advice on trace element analysis; and Dr. Claudia Brodskyn, Dr. 
Mitermayer dos Reis and Dr. Roque Almeida for critical reading of the man-
uscript. Financial support: NIH (TMRC grant AI-30639), CNPq (Brazilian 
National Research Council) and PRONEX. EMC, AB and MBN are CNPq 
investigators. GS received a PIBIC-UFBA and CAPES fellowship.
References
1. Desjeux P: The increase in risk factors for leishmaniasis
worldwide. Trans Roy Soc Trop Med Hyg 2001, 95:239-43.
2. Coffman RL, Chatelain R, Leal LM, Varkila K: Leishmania major
infection in mice: a model system for the study of CD4+ T-
cell subset differentiation. Res Immunol 1991, 142:36-40.
3. Reiner SL, Locksley RM: The regulation of immunity to Leishma-
nia major. Annu Rev Immunol 1995, 13:151-77.
4. Rocha PN, Almeida RP, Bacellar O, de Jesus AR, Filho DC, Filho AC,
Barral A, Coffman RL, Carvalho EM: Down-regulation of Th1 type
of response in early human American cutaneous
leishmaniasis. J Infect Dis 1999, 180:1731-4.
5. Ribeiro-de-Jesus A, Almeida RP, Lessa H, Bacellar O, Carvalho EM:
Cytokine profile and pathology in human leishmaniasis. Braz
J Med Biol Res 1998, 31:143-8.
6. Carvalho EM, Badaro R, Reed SG, Jones TC, Johson WD Jr: Absence
of gamma interferon and interleukin 2 production during
active visceral leishmaniasis. J Clin Invest 1985, 76:2066-9.
7. Badaro R, Falcoff E, Badaro FS, Carvalho EM, Pedral-Sampaio D, Bar-
ral A, Carvalho JS, Barral-Netto M, Brandely M, Silva L: Treatment
of visceral leishmaniasis with pentavalent antimony and
interferon gamma. N Engl J Med 1990, 322:16-21.
8. Beck FW, Prasad AS, Kaplan J, Fitzgerald JT, Brewer GJ: Changes in
cytokine production and T cell subpopulations in experimen-
tally induced zinc-deficient humans.  Am J Physiol 1997,
272:E1002-7.
9. Kocyigit A, Erel O, Gurel MS, Avci S, Akteje N: Alterations of
serum selenium, zinc, copper, and iron concentrations and
some related antioxidant enzyme activities in patients with
cutaneous leishmaniasis. Biol Trace Elem Res 1998, 65:271-81.
10. Dominguez M, Torano A: Immune adherence-mediated
opsonophagocytosis: the mechanism of Leishmania infection.
J Exp Med 1999, 189:25-35.
11. Bogden JD, Kemp FW, Han S, Li W, Bruening K, Denny T, Oleske JM,
Lloyd J, Baker H, Perez G, Kloser P, Skurnick J, Louria DB: Status of
selected nutrients and progression of human immunodefi-
ciency virus type 1 infection. Am J Clin Nutr 2000, 72:809-15.
12. Aston NS, Watt N, Morton IE, Tanner MS, Evans GS: Copper tox-
icity affects proliferation and viability of human hepatoma
cells (HepG2 line). Hum Exp Toxicol 2000, 19:367-76.
13. Van Weyenbergh J: Identification of molecular targets for zinc
regulation of human monocyte metabolism. In PhD Thesis
Catholic University Leuven, Faculty of Sciences; 1995. 
14. Santos MA, Marques RC, Farias CA, Vasconcelos DM, Stewart JM,
Costa DL, Costa CH: Predictors of an unsatisfactory response
to pentavalent antimony in the treatment of American vis-
ceral leishmaniasis. Rev Soc Bras Med Trop 2002, 35:629-33.
15. Werneck GL, Batista MS, Gomes JR, Costa DL, Costa CH: Prognos-
tic factors for death from visceral leishmaniasis in Teresina,
Brazil. Infection 2003, 31:174-7.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Infectious Diseases 2004, 4:50 http://www.biomedcentral.com/1471-2334/4/50
Page 7 of 7
(page number not for citation purposes)
16. Theocharis S, Margeli A, Panayiotidis P: Effects of various metals
on DNA synthesis and lymphokines production by human
peripheral blood lymphocytes in vitro. Comp Biochem Physiol C
1991, 99:131-3.
17. Araya M, Koletzko B, Uauy R: Copper deficiency and excess in
infancy: developing a research agenda. J Pediatr Gastroenterol
Nutr 2003, 37:422-9.
18. Sharifi I, FeKri AR, Aflatonian MR, Aflatonian MR, Khamesipour A,
Nadim A: Randomised vaccine trial of single dose of killed
Leishmania major plus BCG against anthroponotic cutaneous
leishmaniasis in Bam, Iran. Lancet 1998, 351:1540-3.
19. Khalil EA, El Hassan AM, Zijlstra EE, Mukhtar MM, Ghalib H W, Musa
B: Autoclaved Leishmania major vaccine for prevention of vis-
ceral leishmaniasis: a randomised, double-blind, BCG-con-
trolled trial in Sudan. Lancet 2000, 356:1565-9.
20. Brewer GJ: Recognition, diagnosis, and management of Wil-
son's disease. Proc Soc Exp Biol Med 2000, 223:39-46.
21. Sharquie KE, Najim RA, Farjou IB, Al-Timimi DJ: Oral zinc sulphate
in the treatment of acute cutaneous leishmaniasis. Clin Exp
Dermatol 2001, 26:21-6.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2334/4/50/prepub